Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP662234.RAf7KtDygv0zkBSp8qBjotuvC9z5wEvaNNg9Ani48gwic130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP662234.RAf7KtDygv0zkBSp8qBjotuvC9z5wEvaNNg9Ani48gwic130_provenance.
• NP843604.RARpT-Nx_0TieEEQr3dcbN7yvLyUsbRNGa2jFMW5R_YJs130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP843604.RARpT-Nx_0TieEEQr3dcbN7yvLyUsbRNGa2jFMW5R_YJs130_provenance.
• NP379905.RAo2mc6uGnCG0RVxP0Wo31de260N9I9KFeSWqGcnlxVDA130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP379905.RAo2mc6uGnCG0RVxP0Wo31de260N9I9KFeSWqGcnlxVDA130_provenance.
• NP441369.RAeqwTerBQQ4yzk5T097Ka82DmqczK_2JXRFA7qVJyVrs130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP441369.RAeqwTerBQQ4yzk5T097Ka82DmqczK_2JXRFA7qVJyVrs130_provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP333814.RA0E1-SrqTxMYiO-AMKiCtsVUlK06Tvnnm324XCHWL5fY130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP333814.RA0E1-SrqTxMYiO-AMKiCtsVUlK06Tvnnm324XCHWL5fY130_provenance.
• NP741634.RAAnJSCS2sZU_uMyxdc5R1BRPgZEay09X3wh0f38bfmyI130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP741634.RAAnJSCS2sZU_uMyxdc5R1BRPgZEay09X3wh0f38bfmyI130_provenance.
• NP753017.RAh-wVyZ_LPZcjA_5XLzlGrfsTYZLr2DNE6WKwRTMuod0130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP753017.RAh-wVyZ_LPZcjA_5XLzlGrfsTYZLr2DNE6WKwRTMuod0130_provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP200755.RAwkup8lFfUd5rt7cEzX0SaAso5nb1X6B2RwyB7qRo3wU130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP200755.RAwkup8lFfUd5rt7cEzX0SaAso5nb1X6B2RwyB7qRo3wU130_provenance.
• NP236934.RAAB3uo-7479SknKtkyomIkH6KreJnqPMsQ1doRRRk9-4130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP236934.RAAB3uo-7479SknKtkyomIkH6KreJnqPMsQ1doRRRk9-4130_provenance.
• NP284623.RAAX2L7aYHx9PAHcByZ7JMYN-UsyD9PP9BieEvzQJ_Xq8130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP284623.RAAX2L7aYHx9PAHcByZ7JMYN-UsyD9PP9BieEvzQJ_Xq8130_provenance.
• NP791083.RAwMtVM_oG4cuubRbDMPGDLFVkNX5CyZ9kBtAn2KQKRmc130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP791083.RAwMtVM_oG4cuubRbDMPGDLFVkNX5CyZ9kBtAn2KQKRmc130_provenance.
• NP881166.RA1UAOpVLz0Ia6xeNAabzqxvWI--AAhwvkCAOtr_AZDoE130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881166.RA1UAOpVLz0Ia6xeNAabzqxvWI--AAhwvkCAOtr_AZDoE130_provenance.
• NP887836.RADGYe5Znx14qNFZ3czd5avYOVKvN5Dg3pyUQJtaFJyMI130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP887836.RADGYe5Znx14qNFZ3czd5avYOVKvN5Dg3pyUQJtaFJyMI130_provenance.
• NP676648.RA82GQQctUNOFieCo-LReTTfIiwe2QuTh_RHGREWV7ALc130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP676648.RA82GQQctUNOFieCo-LReTTfIiwe2QuTh_RHGREWV7ALc130_provenance.
• NP697860.RAwCx3wXB9CCl2wWJzKnoPWR7o4pjS4kLRRfNG4GtPXdg130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP697860.RAwCx3wXB9CCl2wWJzKnoPWR7o4pjS4kLRRfNG4GtPXdg130_provenance.
• NP894302.RAKb9xCSPqGlwp-LiSrFEU5OTS3MOYYc_NTTefWhWgg_M130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894302.RAKb9xCSPqGlwp-LiSrFEU5OTS3MOYYc_NTTefWhWgg_M130_provenance.
• NP718822.RAAtnxDrMyfMfMxvhBjiSr8rIMQj9TxDgHjSr9R00z8eE130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718822.RAAtnxDrMyfMfMxvhBjiSr8rIMQj9TxDgHjSr9R00z8eE130_provenance.
• NP702311.RAQQO7bkGzSUm5eQwkZoraOMqvewxOn6fZ_9YAlNqTxJc130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP702311.RAQQO7bkGzSUm5eQwkZoraOMqvewxOn6fZ_9YAlNqTxJc130_provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP740281.RAwsLMg-TZw8br0g_HoKoV7nSJe-VqwZkRsMFLQfpQ27Q130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP740281.RAwsLMg-TZw8br0g_HoKoV7nSJe-VqwZkRsMFLQfpQ27Q130_provenance.
• NP881046.RA6OsuCMN-KmZAWnJ34qqyW15sckHJf8WNPgh7du5fyM0130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP881046.RA6OsuCMN-KmZAWnJ34qqyW15sckHJf8WNPgh7du5fyM0130_provenance.
• NP917212.RAzIl6iQfTVnGz-olhILQ_92kVIELml9skxbHoFZFMXM8130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP917212.RAzIl6iQfTVnGz-olhILQ_92kVIELml9skxbHoFZFMXM8130_provenance.
• NP853786.RA5WnZNbU5xStXH2EdvzfmlN8TPEPAwuou5MTW3g6CsUQ130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP853786.RA5WnZNbU5xStXH2EdvzfmlN8TPEPAwuou5MTW3g6CsUQ130_provenance.
• NP718824.RA-xDUj6pR68eHIVeGnV8vke6hPVybjqB4Dhrau2yJe4Y130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718824.RA-xDUj6pR68eHIVeGnV8vke6hPVybjqB4Dhrau2yJe4Y130_provenance.
• NP718829.RA_h0WmxxVlTDVaX8edmSi0ZKH78JtRp8Hs9eOI4SnAM4130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718829.RA_h0WmxxVlTDVaX8edmSi0ZKH78JtRp8Hs9eOI4SnAM4130_provenance.
• NP718820.RAdVycqLw81BdCuDvw0r9a5A1FhWE9_z3lFrovgoSl6fk130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718820.RAdVycqLw81BdCuDvw0r9a5A1FhWE9_z3lFrovgoSl6fk130_provenance.
• NP718825.RAT4qLC3I6mNDfwV8haJ6IeAtfV7R8n3VvFnOY-v5Wc7k130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718825.RAT4qLC3I6mNDfwV8haJ6IeAtfV7R8n3VvFnOY-v5Wc7k130_provenance.
• NP718830.RAR9zfFUk0ksBD2fPPxWxygx6-8PGavVtvXa8bVbM3Sr4130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718830.RAR9zfFUk0ksBD2fPPxWxygx6-8PGavVtvXa8bVbM3Sr4130_provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP718823.RAPoD7LoflUkNb77MymOf3uXLC_HjU4-zqdrGNb8PwFWk130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718823.RAPoD7LoflUkNb77MymOf3uXLC_HjU4-zqdrGNb8PwFWk130_provenance.
• NP718826.RAPTqrdbgEwkLM3DFjooCRV3ftsP1Do6KZ_Csu2W_yas8130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718826.RAPTqrdbgEwkLM3DFjooCRV3ftsP1Do6KZ_Csu2W_yas8130_provenance.
• NP718827.RAE135e_teVSsTlSI544wde-dPuzM031P9mQ7STnkCBoc130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718827.RAE135e_teVSsTlSI544wde-dPuzM031P9mQ7STnkCBoc130_provenance.
• NP718828.RAIQpyWUy24ZKRsnmL0mQbhHo5ERLbE1UzjD7ZmVF4umQ130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718828.RAIQpyWUy24ZKRsnmL0mQbhHo5ERLbE1UzjD7ZmVF4umQ130_provenance.
• NP254883.RApmsdDTFHkKkIbFPs5pH8x0n4LJHd2y9KxNKxWfI7Ba0130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP254883.RApmsdDTFHkKkIbFPs5pH8x0n4LJHd2y9KxNKxWfI7Ba0130_provenance.
• NP718819.RAtnB6POPVL6fnw6Q5qM0ExsYhDwMDUk_9RpreklvI_fg130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718819.RAtnB6POPVL6fnw6Q5qM0ExsYhDwMDUk_9RpreklvI_fg130_provenance.
• NP718821.RAgCdSeal0BAq6j5pd8P7oIzExq_wcIQEKmktpbVAnd1c130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718821.RAgCdSeal0BAq6j5pd8P7oIzExq_wcIQEKmktpbVAnd1c130_provenance.
• NP948021.RAIDAGrqXxr6UJXxdu0Mg4QlOmxsFm-bzsPOmlx1NbUzw130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP948021.RAIDAGrqXxr6UJXxdu0Mg4QlOmxsFm-bzsPOmlx1NbUzw130_provenance.
• assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP268989.RAip4TtfK-FzUYhsVp38zEohd5WXtTe1RTMeEn0X2gQPE130_assertion description "[After stimulation with TLR2 and TLR4 agonists, AVICs express higher levels of pro-inflammatory and pro-osteogenic mediators (bone morphogenetic protein [BMP]-2, runt-related transcription factor 2) and greater osteogenic phenotypic changes (alkaline phosphatase [ALP] activity, calcified nodule formation) than PVICs.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP268989.RAip4TtfK-FzUYhsVp38zEohd5WXtTe1RTMeEn0X2gQPE130_provenance.